Target Price | GBP17.39 |
Price | GBP13.47 |
Potential |
29.13%
register free of charge
|
Number of Estimates | 16 |
16 Analysts have issued a price target GlaxoSmithKline 2025 .
The average GlaxoSmithKline target price is GBP17.39.
This is
29.13%
register free of charge
GBP26.10
93.84%
register free of charge
GBP13.50
0.26%
register free of charge
|
|
A rating was issued by 22 analysts: 9 Analysts recommend GlaxoSmithKline to buy, 10 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the GlaxoSmithKline stock has an average upside potential 2025 of
29.13%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Billion GBP | 30.33 | 31.23 |
3.42% | 2.98% | |
EBITDA Margin | 30.62% | 33.28% |
1.71% | 8.68% | |
Net Margin | 16.41% | 12.91% |
68.20% | 21.34% |
16 Analysts have issued a sales forecast GlaxoSmithKline 2024 . The average GlaxoSmithKline sales estimate is
This results in the following potential growth metrics:
13 Analysts have issued an GlaxoSmithKline EBITDA forecast 2024. The average GlaxoSmithKline EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
12 GlaxoSmithKline Analysts have issued a net profit forecast 2024. The average GlaxoSmithKline net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share GBP | 1.22 | 0.99 |
67.12% | 18.85% | |
P/E | 13.62 | |
EV/Sales | 2.15 |
12 Analysts have issued a GlaxoSmithKline forecast for earnings per share. The average GlaxoSmithKline <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the GlaxoSmithKline stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
GlaxoSmithKline...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.